The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Dobrokhotov I.V.

National Medical Research Center of Cardiology

Veselova O.M.

National Medical Research Center of Cardiology

Lyubimov R.O.

National Medical Research Center of Cardiology

Cardioprotective effect of galanin and its analogues on different experimental models of heart damage

Authors:

Dobrokhotov I.V., Veselova O.M., Lyubimov R.O.

More about the authors

Journal: Russian Cardiology Bulletin. 2021;16(4): 11‑16

DOI: 10.17116/Cardiobulletin20211604111

Read: 2095 times

Download PDF (RU)
Contact the author
Table of contents

CARDIOPROTECTIVE EFFECT OF GALANIN AND ITS ANALOGUES ON DIFFERENT EXPERIMENTAL MODELS OF HEART DAMAGE
CARDIOPROTECTIVE EFFECT OF GALANIN AND ITS ANALOGUES ON DIFFERENT EXPERIMENTAL MODELS OF HEART DAMAGE

To cite this article:

Dobrokhotov IV, Veselova OM, Lyubimov RO. Cardioprotective effect of galanin and its analogues on different experimental models of heart damage. Russian Cardiology Bulletin. 2021;16(4):11‑16. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20211604111

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

ABSRTACT

Coronary artery disease (CAD) is essential in mortality and disability in the developed countries and diagnosed in more than 40% of people aged 50—70 years. Therefore, searching for new more effective drugs for prevention and treatment of coronary artery disease is necessary. This review is devoted to various experimental data in vivo obtained in animals with heart damage. Considering modern data, we can recognize neuropeptide galanin and its modified N-terminal fragments as potential cardioprotective agents. Galanin receptor ligands improve energy status in heart tissues, decrease of oxidative stress and increase activity of antioxidant enzymes, significantly reduce dimensions of myocardial infarction and levels of creatine kinase and lactate dehydrogenase.

Keywords:

galanin
ischemia
heart
reperfusion
doxorubicin
GalR2 receptor
peptide cardioprotectors
solid phase synthesis

Authors:

Dobrokhotov I.V.

National Medical Research Center of Cardiology

Veselova O.M.

National Medical Research Center of Cardiology

Lyubimov R.O.

National Medical Research Center of Cardiology

Received:

03.04.2021

Accepted:

27.08.2021

Close metadata

References:

  1. Lang R, Gundlach AL, Holmes FE, Hobson SA, Wynick D, Hökfelt T, Kofler B. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacological Reviews. 2015;67(1):118-175.  https://doi.org/10.1124/pr.112.006536
  2. Fang P, Yu M, Shi M, Zhang Z, Sui Y, Guo L, Bo P. Galanin peptide family as a modulating target for contribution to metabolic syndrome. General and Comparative Endocrinology. 2012;179(1):115-120.  https://doi.org/10.1016/j.ygcen.2012.07.029
  3. Waters SM, Krause JE. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience. 2000;95(1):265-271.  https://doi.org/10.1016/S0306-4522(99)00407-8
  4. Wang S, He C, Hashemi T, Bayne M. Cloning and expressional characterization of a novel galanin receptor. Identification of different pharmacophores within galanin for the three galanin receptor subtypes. The Journal of Biological Chemistry. 1997;272(51):31949-31952. https://doi.org/10.1074/jbc.272.51.31949
  5. Diaz-Cabiale Z, Parrado C, Vela C, Razani H, Coveñas R, Fuxe K, Narváez JA. Role of galanin and galanin (1—15) on central cardiovascular control. Neuropeptides. 2005;39(3):185-190.  https://doi.org/10.1016/j.npep.2004.12.009
  6. Palkeeva ME, Sidorova MV, Molokoedov AS, Ovchinnikov MV, Az’muko AA, Serebryakova LI, Veselova OM, Studneva IM, Pisarenko OI. Fragments of the Galanin Peptide and Their Synthetic Analogues with the Cardioprotective Effect. Bioorganicheskaya himiya. 2019;45(5):510-517. (In Russ.). https://doi.org/10.1134/S1068162019040071
  7. Sidorova MV, Palkeeva ME, Avdeev DV, Molokoedov AS, Ovchinnikov MV, Azmuko AA, Serebryakova LI, Veselova OM, Studneva IM, Pisarenko OI. Convergent synthesis of the rat galanin and study of its biological activity. Bioorganicheskaya himiya. 2020;46(1):32-42. (In Russ.). https://doi.org/10.31857/S0132342320010121
  8. Liu HX, Brumovsky P, Schmidt R, Brown W, Payza K, Hodzic L, Pou C, Godbout C, Hökfelt T. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(17):9960-9964. https://doi.org/10.1073/pnas.161293598
  9. Lu X, Lundström L, Bartfai T. Galanin (2-11) binds to GalR3 in trans-fected cell lines: Limitations for pharmacological definition of receptor subtypes. Neuropeptides. 2005;39(3):165-167.  https://doi.org/10.1016/j.npep.2004.12.013
  10. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discovery Today. 2010;15(1/2):40-56.  https://doi.org/10.1016/j.drudis.2009.10.009
  11. Zhao J, Posa DK, Kumar V, Hoetker D, Kumar A, Ganesan S, Riggs DW, Bhatnagar A, Wempe MF, Baba SP. Carnosine protects cardiac myocytes against lipid peroxidation products. Amino Acids. 2019;51(1):123-138.  https://doi.org/10.1007/s00726-018-2676-6
  12. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Progress in Cardiovascular Diseases. 2007;49(5):330-352.  https://doi.org/10.1016/j.pcad.2006.10.002
  13. Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer current evidence and underlying mechanisms. Circulation. 2011;124(5):642-650.  https://doi.org/10.1161/CIRCULATIONAHA.111.021774
  14. Nebigil CG, Désaubry L. Updates in anthracycline-mediated cardiotoxicity. Frontiers in Pharmacology. 2018;9:1262. https://doi.org/10.3389/fphar.2018.01262
  15. Studneva I, Palkeeva M, Veselova O, Molokoedov A, Ovchinnikov M, Sidorova M, Pisarenko O. Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats. Cardiovascular Toxicology. 2019;19(2):136-146.  https://doi.org/10.1007/s12012-018-9483-x
  16. Serebryakova LI, Pal’keeva ME,Studneva IM, Ovchinnikov MV, Veselova OM, Molokoedov AS, Az’muko AA, Arzamastsev EV, Afanasyeva EYu, Terekhova OA, Sidorova MV, Pisarenko OI. Cardiometabolic efficacy and toxicological evaluation of a pharmacological galanin receptor agonist. Biomeditsinskaya khimiya, 2019;65(3):231-238. (In Russ.). https://doi.org/10.18097/PBMC20196503231
  17. Studneva IM, Veselova OM, Bahtin AA, Konovalova GG, Lankin VZ, Pisarenko OI. Mechanisms of Cardiac Protection Using a Synthetic Agonist of Galanin Receptors during Chronic Administration of Doxorubicin. Acta Naturae. 2020;12(1):89-98. (In Russ.). https://doi.org/10.32607/actanaturae.10945
  18. Shulzhenko VS, Serebryakova LI, Studneva IM, Pelogejkina YuA, Veselova OM, Molokoedov AS, Ovchinnikov MV, Palkeeva ME, Sidorova MV, Pisarenko OI. Ability of n-terminal fragment of neuropeptide galanin to attenuate ischemia and reperfusion injury of rat heart. Kardiologicheskij vestnik. 2016;11(3):12-21. (In Russ.). https://readera.org/14334787
  19. Palkeeva M, Studneva I, Molokoedov A, Serebryakova L, Veselova O, Ovchinnikov M, Sidorova M, Pisarenko O. Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia reperfusion injury. Biomedicine and Pharmacotherapy. 2019;109:1556-1562. https://doi.org/10.1016/j.biopha.2018.09.182
  20. Serebryakova L, Pal’keeva M, Studneva I, Molokoedov A, Veselova O, Ovchinnikov M, Gataulin R, Sidorova M, Pisarenko O. Galanin and its N-terminal fragments reduce acute myocardial infarction in rats. Peptides. 2019;111:127-131.  https://doi.org/10.1016/j.peptides.2018.05.001
  21. Varricchi G, Galdiero MR, Tocchetti CG. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation. 2017;136(21):1989-1992. https://doi.org/10.1161/CIRCULATIONAHA.117.029626
  22. Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Scientific Reports. 2017;7:44735. https://doi.org/10.1038/SREP44735
  23. Dhingra R, Margulets V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, Dorn GW, Kirshenbaum LA. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(51):5537-5544. https://doi.org/10.1073/pnas.1414665111
  24. Venardos KM, Perkins A, Headrick J, Kaye DM. Myocardial ischemiareperfusion injury, antioxidant enzyme systems, and selenium. Current Medicinal Chemistry. 2007;14(14):1539-1549. https://doi.org/10.2174/092986707780831078
  25. Indo HP, Yen HC, Nakanishi I, Matsumoto K, Tamura M, Nagano Y, Matsui H, Gusev O, Cornette R, Okuda T, Minamiyama Y, Ichikawa H, Suenaga S, Oki M, Sato T, Ozawa T, Clair DK, Majima HJ. A mitochondrial superoxide theory for oxidative stress diseases and aging. Journal of Clinical Biochemistry and Nutrition. 2015;56(1):1-7.  https://doi.org/10.3164/jcbn.14-42
  26. Studneva I, Serebryakova L, Veselova O, Pal’keeva M, Molokoedov A, Ovchinnikov M, Konovalova G, Lankin V, Sidorova M, Pisarenko O. Galanin receptors activation modulates myocardial metabolic and antioxidant responses to ischaemia reperfusion stress. Clinical and Experimental Pharmacology and Physiology. 2019;46(12):1174-1182. https://doi.org/10.1111/1440-1681.13164
  27. Tokarska-Schlattner M, Wallimann T, Schlattner U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. Comptes Rendus Biologies. 2006;329(9):657-668.  https://doi.org/10.1016/j.crvi.2005.08.007
  28. Timotin A, Cinato M, Kramar S, Timotin A, Cinato M, Kramar S, Loy H, Merabishvili G, Boal F, Tronchere H, Kunduzova O. Galanin is a checkpoint regulator of mitochondrial biogenesis coordinating a pro-survival phenotype in post-infarct myocardial remodeling. SSRN Electronic Journal. 2019. Accessed May 25, 2021. https://doi.org/10.2139/ssrn.3424189
  29. Timotin A, Pisarenko O, Sidorova M, Studneva I, Shulzhenko V, Palkeeva M, Serebryakova L, Molokoedov A, Veselova O, Cinato M, Tronchere H, Boal F, Kunduzova O. Myocardial protection from ischemia/reperfusion injury by exogenous galanin fragment. Oncotarget. 2017;8(13):21241-21252. https://doi.org/10.18632/oncotarget.15071
  30. Power O, Jakeman P, FitzGerald RJ. Antioxidative peptides: enzymatic production, in vitro and in vivo antioxidant activity and potential applications of milk-derived antioxidative peptides. Amino Acids. 2013;44(3):797-820.  https://doi.org/10.1007/s00726-012-1393-9
  31. Dobrokhotov IV, Veselova OM, Lyubimov RO. Potential role of galanine in the treatment of type 2 diabetes mellitus. Saharnyj diabet. 2020;23(4):368-373. (In Russ.). https://doi.org/10.14341/DM10195
  32. Fang P, Yu M, He B, Guo L, Huang X, Kong G, Shi M, Zhu Y, Bo P, Zhang Z. Central injection of GALR1 agonist M617 attenuates diabetic rat skeletal muscle insulin resistance through the Akt/AS160/GLUT4 pathway. Mechanisms of Ageing and Development. 2017;162:122-128.  https://doi.org/10.1016/j.mad.2016.03.013
  33. Bu L, Yao Q, Liu Z, Tang W, Zou J, Qu S. Combined galanin with insulin improves insulin sensitivity of diabetic rat muscles. The Journal of Endocrinology. 2014;221(1):157-165.  https://doi.org/10.1530/JOE-13-0444
  34. Kim A, Park T. Diet-induced obesity regulates the galanin-mediated signaling cascade in the adipose tissue of mice. Molecular Nutrition and Food Research. 2010;54(9):1361-1370. https://doi.org/10.1002/mnfr.200900317
  35. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405(6785):421-424.  https://doi.org/10.1038/35013000
  36. Thong FS, Bilan PJ, Klip A. The Rab GTPase-activating protein AS160integrates Akt, protein kinase C, and AMP-activated protein kinase signals regulatingGLUT4 traffic. Diabetes. 2007;56(2):414-423.  https://doi.org/10.2337/db06-0900
  37. Fang P, Yu M, Shi M, Bo P, Zhang Z. Galanin peptide family regulation of glucose metabolism. Frontiers in Neuroendocrinology. 2020;56:100801. https://doi.org/10.1016/j.yfrne.2019.100801
  38. Tian R, Abel E. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation. 2001;103(24):2961-2966. https://doi.org/10.1161/01.cir.103.24.2961
  39. Runesson J. Galanin Receptor Ligands. Stockholm University; 2009. Accessed May 25, 2021. https://su.diva-portal.org/smash/get/diva2:430469/FULLTEXT01.pdf
  40. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovascular Research. 2003;60(3):617-625.  https://doi.org/10.1016/j.cardiores.2003.09.025
  41. Mollie A, Jun R. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Current Diabetes Reviews. 2007;3(1):33-39.  https://doi.org/10.2174/157339907779802067
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.